stockrow
Monday 9 November 2026
Export PDSB’s income statement to Excel — free account
PDS Biotechnology Corporation
PDSB- EPS
- +14.3%
- Free cash flow
- +69.3%
- Total debt
- −66.6%
Quarter to June 2026, against a year earlier
1.23
0.06
+5.13%
Follow PDSB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | 9 | 2 | (79.7%) | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (41) | (53) | (4) | (7) | (15) | (21) | (42) | (44) | (38) | (36) | (34) | (1.4%) | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (39) | (51) | (4) | (7) | (15) | (17) | (41) | (43) | (38) | (34) | (34) | (1.3%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (26.80) | (33.40) | (1.15) | (1.44) | (0.89) | (0.66) | (1.43) | (1.39) | (1.03) | (0.74) | (0.64) | (32.9%) | ||||||
| Cash flow | (22.30) | (26.78) | (0.47) | (3.71) | (0.79) | (0.49) | (0.90) | (1.09) | (0.96) | (0.60) | (0.30) | (33.1%) | ||||||
| Capex | (0.48) | (0.12) | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (22.78) | (26.90) | (0.47) | (3.66) | (0.79) | (0.49) | (0.90) | (1.09) | (0.96) | (0.60) | (0.30) | (33.3%) | ||||||
| Book value | 61.86 | 41.04 | (0.62) | 2.40 | 1.62 | 2.47 | 1.54 | 0.84 | 0.52 | 0.20 | (0.06) | (47.1%) | ||||||
| Shares, m | 1 | 2 | 3 | 5 | 17 | 26 | 29 | 31 | 36 | 46 | 51 | +47.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (32) | (41) | (2) | (18) | (13) | (12) | (26) | (34) | (35) | (28) | (17) | (1.6%) | |||||
| Capex | (1) | 0 | — | 0 | — | — | — | — | 0 | — | 0 | (32.7%) | ||||||
| Free cash flow | (33) | (41) | (2) | (18) | (13) | (12) | (26) | (34) | (35) | (28) | (17) | (1.9%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 101 | 76 | (2) | 12 | 27 | 63 | 67 | 45 | 28 | 19 | (5) | (17.0%) | |||||
| Net debt | (91) | (68) | 0 | (12) | (28) | (65) | (51) | (37) | (32) | (15) | (1) | (18.2%) | ||||||
| Shareholders’ equity | 89 | 62 | (2) | 12 | 27 | 63 | 44 | 26 | 19 | 9 | (4) | (22.3%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (31.69) | (49.98) | (8.27) | (95.51) | (65.43) | (34.50) | (56.66) | (62.97) | (71.81) | (90.95) | (136.65) | (59.3) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (36.67) | (67.08) | (12.72) | (145.33) | (76.48) | (37.46) | (76.21) | (122.46) | (166.65) | (244.16) | (543.97) | (207.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 31 | 38 | 10 | 15 | 15 | 22 | 26 | 25 | 24 | 21 | — | (4.2%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
PDS Biotechnology Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| YARW Yarrow Bioscience, Inc | $147.2M | — (loss-making) | — (loss-making) | +40.58% (above 0%: growing) | n/m | +81.56% (above 0%: growing) | 100.00% | (3,197.94%) | Compare |
| CMPX Compass Therapeutics, Inc. | $136.7M | — (loss-making) | — (loss-making) | — | n/m | −26.05% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CUE Cue Biopharma, Inc. | $136.1M | — (loss-making) | — (loss-making) | +166.66% (above 0%: growing) | n/m | −742.65% (below 0%: shrinking) | 100.00% | (1,113.30%) | Compare |
| TARA Protara Therapeutics, Inc. | $135.9M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SPRB Spruce Biosciences, Inc. | $133.8M | — (loss-making) | — (loss-making) | −75.86% (below 0%: shrinking) | n/m | −152.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MENS Jyong Biotech Ltd. | $133.6M | — | — | — | — | — | — | — | Compare |
| PDSB PDS Biotechnology Corporation | $129.2M | — (loss-making) | — | — | n/m | +69.32% (above 0%: growing) | 0.00% | 0.00% | |
| MOLN Molecular Partners AG Sponsored ADR | $119.2M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +11.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CHRS Coherus Oncology, Inc. | $119.0M | — (loss-making) | — (loss-making) | +39.53% (above 0%: growing) | n/m | −33.15% (below 0%: shrinking) | 70.35% | (225.98%) | Compare |
| Median of peers | $134.9M | — | — | +39.53% | — | −28.10% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 26 June 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 828.31k | 630.19k | 5.83 |
| 2024 | 2.26m | (217.79k) | 12.35 |
| 2023 | 5.01m | (2.39m) | 37.65 |
Ownership
Directors and executive officers, together
8.40%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement